Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Retained Earnings (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Retained Earnings for 6 consecutive years, with -$25000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings changed 0.0% year-over-year to -$25000.0, compared with a TTM value of -$25000.0 through Dec 2025, changed 0.0%, and an annual FY2025 reading of -$25000.0, changed 0.0% over the prior year.
  • Retained Earnings was -$25000.0 for Q4 2025 at Xeris Biopharma Holdings, up from -$682.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$23000.0 in Q4 2022 and bottomed at -$683.0 million in Q2 2025.
  • Average Retained Earnings over 5 years is -$319.4 million, with a median of -$434.7 million recorded in 2021.
  • The sharpest move saw Retained Earnings crashed 7668600.0% in 2021, then surged 100.0% in 2025.
  • Year by year, Retained Earnings stood at -$460.1 million in 2021, then soared by 100.0% to -$23000.0 in 2022, then decreased by 8.7% to -$25000.0 in 2023, then changed by 0.0% to -$25000.0 in 2024, then changed by 0.0% to -$25000.0 in 2025.
  • Business Quant data shows Retained Earnings for XERS at -$25000.0 in Q4 2025, -$682.4 million in Q3 2025, and -$683.0 million in Q2 2025.